News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2020

30 December, 2020 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
22 December, 2020 Nomination Committee appointed for the 2021 Annual General Meeting in Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
17 December, 2020 PledPharma changes its name to Egetis Therapeutics with focus on late stage orphan drug development News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
15 December, 2020 Results from the prematurely closed PledOx POLAR program News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
11 December, 2020 Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 11 December 2020 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
30 November, 2020 Change in the number of shares and votes in PledPharma News Corporate Action Shares Issuance English Regulatory LHFI IR Optional
25 November, 2020 PledPharma raises SEK 250 million in oversubscribed rights issue and utilized overallotment option News Corporate Action Shares Issuance English Regulatory MAR IR Optional
23 November, 2020 Clarification regarding ownership changes in PledPharma News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
12 November, 2020 PledPharma publishes a supplement to the prospectus News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
11 November, 2020 Interim Report January 1-September 30, 2020 News English Regulatory MAR Report Interim Q3 IR Optional
10 November, 2020 NOTICE TO ATTEND EXTRAORDINARY GENERAL MEETING IN PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
6 November, 2020 Henrik Krook appointed VP Commercial Operations at PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
5 November, 2020 PledPharma publishes prospectus and updated financial information in connection with fully guaranteed rights issue and the admission to trading of shares News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
28 October, 2020 Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 28 October 2020 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
20 October, 2020 Nomination Committee appointed for the 2021 Annual General Meeting in PledPharma News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
5 October, 2020 Notice of Extraordinary general meeting in PledPharma AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
5 October, 2020 PledPharma to acquire Rare Thyroid Therapeutics, creating a new focused orphan drug development company News Corporate Action M&A English Regulatory MAR IR Optional
20 August, 2020 Half-Year report January-June 2020 News English Regulatory MAR VPML Report Interim Q2 IR Optional
30 July, 2020 Changes in PledPharma’s Board of Directors and committees News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
24 June, 2020 Marie-Louise Alamaa appointed interim CFO at PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
26 May, 2020 CFO Yilmaz Mahshid leaves PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional
23 April, 2020 Kommuniké från årsstämman i PledPharma AB (publ) News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
22 April, 2020 Interim report January-March 2020 News English Regulatory MAR Report Interim Q1 IR Optional
6 April, 2020 PledPharma to close POLAR phase 3 program in the third quarter News Corporate Action Other English Regulatory MAR IR Optional

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com